Education
About Us
Working with TipRanks
Follow Us
Staar Surgical Company (STAA)
NASDAQ:STAA
STAA Stock Chart & Stats
$25.25
-$1.18(-4.94%)
At close: 4:00 PM EST
$25.25
-$1.18(-4.94%)
Day’s Range― - ―
52-Week Range$13.50 - $30.81
Previous CloseN/A
Volume326.32K
Average Volume (3M)1.30M
Market Cap
$942.61M
Enterprise Value$798.45M
Total Cash (Recent Filing)$192.66M
Total Debt (Recent Filing)$39.12M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Feb 25, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding49,741,955
10 Day Avg. Volume1,019,713
30 Day Avg. Volume1,301,517
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.99
Price to Sales (P/S)3.79
P/FCF Ratio-155.08
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue3.46
Enterprise Value/Gross Profit4.69
Enterprise Value/Ebitda-14.72
Forecast
1Y Price Target
$21.92Price Target Upside-13.19% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition DynamicsAlcon's increased acquisition bid and amended compensation terms improve the chances of securing shareholder and proxy-adviser support, which could ease path to a negotiated transaction.
Board CompositionBroadwood Partners' board appointment and the addition of major shareholder representatives increase the prospect of a strategic refocus on profitability and disciplined growth initiatives.
Product ExecutionAnalyst notes the EVO ICL product demonstrates strong technical performance and effective program execution, supporting potential adoption and clinic-level confidence.
Bears Say
Addressable Market LimitationsAnalyst highlights that the EVO ICL targets a relatively small, high-myopia, out-of-pocket patient pool, limiting the company's long-term market expansion potential.
China Market DemandAnalyst warns that weak demand and rising competition in the Chinese ophthalmic market constrain sales visibility and could pressure revenue growth prospects.
Corporate Governance And Strategic UncertaintyShareholder rejection of the proposed acquisition and planned efforts to replace directors create boardroom turmoil that may distract leadership and hinder operational execution.
Staar Surgical News
STAA FAQ
What was Staar Surgical Company’s price range in the past 12 months?
Staar Surgical Company lowest stock price was $13.50 and its highest was $30.81 in the past 12 months.
What is Staar Surgical Company’s market cap?
Staar Surgical Company’s market cap is $942.61M.
When is Staar Surgical Company’s upcoming earnings report date?
Staar Surgical Company’s upcoming earnings report date is Feb 25, 2026 which is in 23 days.
How were Staar Surgical Company’s earnings last quarter?
Staar Surgical Company released its earnings results on Nov 05, 2025. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.246 by $0.094.
Is Staar Surgical Company overvalued?
According to Wall Street analysts Staar Surgical Company’s price is currently Overvalued.
Does Staar Surgical Company pay dividends?
Staar Surgical Company does not currently pay dividends.
What is Staar Surgical Company’s EPS estimate?
Staar Surgical Company’s EPS estimate is 0.18.
How many shares outstanding does Staar Surgical Company have?
Staar Surgical Company has 49,741,955 shares outstanding.
What happened to Staar Surgical Company’s price movement after its last earnings report?
Staar Surgical Company reported an EPS of $0.34 in its last earnings report, beating expectations of $0.246. Following the earnings report the stock price went up 5.465%.
Which hedge fund is a major shareholder of Staar Surgical Company?
Currently, no hedge funds are holding shares in STAA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Staar Surgical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$21.92 (-13.19% Downside)
$21.92 (-13.19% Downside)
Blogger Sentiment
Bullish
STAA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 720.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $50.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.94%
12-Months-Change
Fundamentals
Return on Equity
-24.65%
Trailing 12-Months
Asset Growth
-15.11%
Trailing 12-Months
Company Description
Staar Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
STAA Stock 12 Month Forecast
Average Price Target
$21.92
▼(-13.19% Downside)
Technical Analysis
Ownership Overview
Currently, No data available
---